The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
According to Myriad, a similar deal is in the works with the pharmacy benefit management services provider for its GeneSight pharmacogenetic test.
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
Mother Jones reports that some data used for interpreting what BRCA1 or BRCA2 mutations mean are kept private.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.